Sigyn Therapeutics is a development-stage company focused on the creation of therapeutic solutions that address unmet needs in global health. Sigyn Therapy™, the Company’s lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies.
Company profile
Ticker
SIGY
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Reign Resources Corp, Reign Sapphire Corp
SEC CIK
Latest filings (excl ownership)
10-K
2023 FY
Annual report
20 Feb 24
8-K
Other Events
31 Jan 24
8-K
Material Modifications to Rights of Security Holders
30 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Other Events
26 Oct 23
8-K
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
4 Oct 23
S-1/A
IPO registration (amended)
22 Sep 23
Latest ownership filings
SC 13G/A
Brio Capital Master Fund Ltd.
8 Feb 24
SC 13G/A
Brio Capital Master Fund Ltd.
4 Feb 22
SC 13G/A
Brio Capital Master Fund Ltd.
27 Jan 21
SC 13G/A
ALPHA CAPITAL ANSTALT
14 Jan 21
SC 13G
Osher Capital Partners LLC
29 Oct 20
SC 13G/A
Reign Sapphire Corp
4 Feb 20
SC 13G/A
Reign Sapphire Corp
4 Feb 19
SC 13G/A
Reign Sapphire Corp
16 Nov 18
SC 13G
Reign Sapphire Corp
2 Mar 18
SC 13G/A
Reign Sapphire Corp
26 Jan 18
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.58 k | 64.58 k | 64.58 k | 64.58 k | 64.58 k | 64.58 k |
Cash burn (monthly) | (no burn) | (no burn) | 301.91 k | 319.07 k | 121.35 k | 142.26 k |
Cash used (since last report) | n/a | n/a | 1.80 mm | 1.90 mm | 721.53 k | 845.84 k |
Cash remaining | n/a | n/a | -1.73 mm | -1.83 mm | -656.94 k | -781.25 k |
Runway (months of cash) | n/a | n/a | -5.7 | -5.7 | -5.4 | -5.5 |
Institutional ownership, Q3 2021
14.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 6.15 mm |
Total shares | 6.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Osher Capital Partners | 3.42 mm | $6.15 mm |
Brio Capital Master Fund | 3.42 mm | $0.00 |